116 related articles for article (PubMed ID: 7527654)
21. A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.
Verma S; Quirt IC; Eisenhauer EA; Iscoe NA; Young VJ; Bodurtha AJ; Davidson J
Ann Oncol; 1993 Mar; 4(3):254-5. PubMed ID: 8471559
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study.
Dreicer R; Propert KJ; Kuzel T; Kirkwood JM; O'Dwyer PJ; Loehrer PJ
Am J Clin Oncol; 1997 Jun; 20(3):251-3. PubMed ID: 9167747
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Shum KY; Kris MG; Gralla RJ; Burke MT; Marks LD; Heelan RT
J Clin Oncol; 1988 Mar; 6(3):446-50. PubMed ID: 2832548
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of 10-deazaaminopterin for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Hollander P; Watson RC
Anticancer Res; 1984; 4(6):409-10. PubMed ID: 6517533
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.
Souhami RL; Rudd RM; Spiro SG; Allen R; Lamond P; Harper PG
Cancer Chemother Pharmacol; 1992; 30(6):465-8. PubMed ID: 1327568
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of edatrexate in previously treated ovarian cancer. A Gynecologic Oncology Group study.
Broun ER; Iseminger KA; Bookman M
Am J Clin Oncol; 1995 Apr; 18(2):164-6. PubMed ID: 7900709
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
[TBL] [Abstract][Full Text] [Related]
28. Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.
Casper ES; Christman KL; Schwartz GK; Johnson B; Brennan MF; Bertino JR
Cancer; 1993 Aug; 72(3):766-70. PubMed ID: 8392904
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer.
Hartley JM; Nicholson PW; Allen R; Lamond P; Harland SJ; Souhami RL
Cancer Chemother Pharmacol; 1993; 31(4):328-32. PubMed ID: 8380758
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Rigas JR; Kris MG; Miller VA; Pisters KM; Heelan RT; Grant SC; Fennelly DW; Chou TC; Sirotnak FM
Ann Oncol; 1999 May; 10(5):601-3. PubMed ID: 10416013
[TBL] [Abstract][Full Text] [Related]
32. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
[TBL] [Abstract][Full Text] [Related]
33. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Pisters KM; Tyson LB; Tong W; Fleisher M; Miller VA; Grant SC; Pfister DG; Rigas JR; Densmore CL; Krol G; Heelan RT; Sirotnak FM; Bertino JR; Kris MG
Clin Cancer Res; 1996 Nov; 2(11):1819-24. PubMed ID: 9816135
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of 10 deaza-aminopterin in patients with bladder cancer.
Ahmed T; Yagoda A; Scher HI; Sternberg C; Watson RC
Invest New Drugs; 1986; 4(2):171-4. PubMed ID: 3733377
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
Knowling M; Bramwell V; Eisenhauer E; Boos G; Bodurtha A; Quirt I
Ann Oncol; 1994 Oct; 5(8):766-8. PubMed ID: 7826912
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.
Casper ES; Schwartz GK; Johnson B; Kelsen DP
Invest New Drugs; 1992 Nov; 10(4):313-6. PubMed ID: 1487406
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of cisplatin in patients with hepatocellular carcinoma.
Okada S; Okazaki N; Nose H; Shimada Y; Yoshimori M; Aoki K
Oncology; 1993; 50(1):22-6. PubMed ID: 7678453
[TBL] [Abstract][Full Text] [Related]
39. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
40. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
